Clinical trial
A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation
Name
Pro00045700
Description
The objective of this study is to make T-cell depleted stem cells from a family member who is a half match (haplo-identical) available on an expanded access basis to patients receiving one or two unrelated cord blood transplants who are at a higher risk of not engrafting in a safe amount of time. The purpose of the related stem cells is the give the bone marrow a "jump start" towards recovery. Ultimately, the cord blood cells will grow and permanently rescue the bone marrow.
Trial arms
Treatment
CliniMACS CD34 Reagent System
The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
Size
-1
Eligibility criteria
Inclusion Criteria:
* Have a consenting related haplo-identical (3/6, 4/6, or 5/6 if DRB1 mismatch) stem cell donor.
* Have one or two available 4, 5, or 6/6 antigen matching unrelated UCB unit(s) that will deliver a total cell dose \>3.0 x 10e7 cells/kg. Patients who do not have a single UCB unit that will deliver the minimum required cell dose, two partially HLA-matched UCB units which together meet the minimum cell dose requirement, can be used for 1 transplant. These units must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing) loci with the patient, and HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with each other (using same resolution of HLA typing as indicated above). There is no limitation on maximum cell dose.
* Have a high risk or refractory malignancy, or non-malignant disorder amenable to stem cell transplantation therapy.
* Meet eligibility requirements for allogeneic transplant per institutional standard practices.
* Have given written informed consent according to FDA guidelines (or consent of parent/legal guardian as applicable).
* Be \<65 years of age at the time of study enrollment.
Exclusion Criteria:
* Have a consenting 8/8 or 10/10 allele matched, consenting, related or unrelated hematopoietic stem cell transplant (HSCT) donor.
* Have a life expectancy of less than 3 months.
* Have uncontrolled infections at time of cytoreduction.
Protocol
{'studyType': 'EXPANDED_ACCESS'}
Updated at
2023-11-13
1 organization
1 product
3 indications
Organization
Joanne KurtzbergIndication
Hematologic MalignanciesIndication
Inborn Errors of Metabolism DisordersIndication
Primary Immunodeficiency